Calcium gluconate
As of the edition of 20 October 2026, Calcium gluconate is a small molecule: marketed, first approved in 2009 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Calciumgluconat
- First approved
- 26 January 2009 (CH)
- Approvals on record
- 12 in 4 regions
- Holder of the most recent approval
- Clinigen; 5 holders in all
- Registered trials
- 19, 3 stopped early
- Disease areas
- Cancer; Nutrition and metabolism; Urinary and reproductive; Bones, joints and muscles; Pregnancy and women's health; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 2 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 4 | 2 | 2 | 0 |
| Phase 3 | 7 | 3 | 1 | 3 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Fresenius Kabi | Applicant | 2017 to now |
| Hq Specialty Pharma | Later holder | 2018 to now |
| Baxter Healthcare | Applicant | 2021 to now |
| Clinigen | Applicant | 2025 to now |